GHP Q2 2023 commitment and activation state of the T cells are read out using single-cell RNA sequencing. Using CRISPR/Cas9 perturbation, Myllia is able to assess the impact of single gene perturbations on the specific T cell phenotype. Finally, the use of CRISPR screens in T cells could help optimise CAR-T cell potency by identifying novel T cell-intrinsic factors involved in activation, exhaustion, and survival mechanisms. In the future, Myllia has two major goals. Currently, screens are limited in terms of the scale at which they are applied. As a result, CROP-seq screens have been considered a valuable tool for target validation, where a limited set of candidate genes are perturbed. Beyond this, Myllia wants to extend this offering and carry out CROP-seq screens at genome-scale, perturbing all 20,000 human genes at once. This will enable the company to provide comprehensive and unbiased analysis and position CROP-seq as a tool for drug target discovery. Secondly, Myllia plans to extend its screening platform beyond primary human T cells to other immune cell types such as macrophages, natural killer cells, B lymphocytes, and many more. This will allow users to address questions that extend far beyond the immunology of T lymphocytes, therefore covering innate and adaptive immunity. As a result of its ground-breaking work in relation to CRISPR screening and drug discovery, Myllia Biotechnology has been awarded Most Innovative BioTech Company, Austria, in the GHP Global Excellence Awards 2023. We congratulate the company on this admirable achievement. With big plans for the future, there is no doubt that Myllia will continue to innovate and succeed in its fundamental industry. Contact: Tilmann Burckstummer Company: Myllia Biotechnology Web Address: www.myllia.com Isolation of cells a b Cas9 + Pooled sgRNA library NK cells B cells T cells Macrophages CRISPR perturbations and scRNA-seq Bioinformatics Single-cell CRISPR screens in primary human blood cells. (a) Primary T cells, B cells, nature killer (NK) cells or macrophages are isolated from human blood. (b) Following isolation, cells are transduced with Cas9 and a suitable guide RNA (sgRNA) library in a pooled fashion. Transcriptomic phenotypes are then assessed by single-cell RNA sequencing (scRNA-seq) and bioinformatics analysis. GHP Q2 2023 commitment and activation state of the T cells are read out using single-cell RNA sequencing. Using CRISPR/Cas9 perturbation, Myllia is able to assess the impact of single gene perturbations on the speci c T cell phenotype. Finally, the use of CRISPR screens in T cells could help optimise CAR-T cell potency by identifying novel T cell-intrinsic factors involved in activation, exhaustion, and survival mechanisms. In the future, Myllia has two major goals. Currently, screens are limited in terms of the scale at which they are applied. As a result, CROP-seq screens have been considered a valuable tool for target validation, where a limited set of candidate genes are perturbed. Beyond this, Myllia wants to extend this o ering and carry out CROP-seq screens at genome-scale, perturbing all 20,000 human genes at once. This will enable the company to provide comprehensive and unbiased analysis and position CROP-seq as a tool for drug target discovery. Secondly, Myllia plans to extend its screening platform beyond primary human T cells to other immune cell types such as macrophages, natural killer cells, B lymphocytes, and many more. This will allow users to address questions that extend far beyond the immunology of T lymphocytes, therefore covering innate and adaptive immunity. As a result of its ground-breaking work in relation to CRISPR screening and drug discovery, Myllia Biotechnology has been awarded Most Innovative BioTech Company, Austria, in the GHP Global Excellence Awards 2023. We congratulate the company on this admirable achievement. With big plans for the future, there is no doubt that Myllia will continue to innovate and succeed in its fundamental industry. Contact: Tilmann Burckstummer Company: Myllia Biotechnology Web Address: www.myllia.com Isolation of cells a b Cas9 + Pooled sgRNA library NK cells B cells T cells Macrophages CRISPR perturbations and scRNA-seq Bioinformatics Single-cell CRISPR screens in primary human blood cells. (a) Primary T cells, B cells, nature killer (NK) cells or macrophages are isolated from human blood. (b) Following isolation, cells are transduced with Cas9 and a suitable guide RNA (sgRNA) library in a pooled fashion. Transcriptomic phenotypes are then assessed by single-cell RNA sequencing (scRNA-seq) and bioinformatic analyses. GHP Global Excellence Awards 2023
RkJQdWJsaXNoZXIy NTY1MjM3